B. Gaillac

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial

Abdel-Rahmène Azzouzi, S. Vincendeau, Éric Barret et al. · The Lancet Oncology · 2016 · 330 citations

Medicine, Oncology, Pharmacology +15

Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using <scp>WST</scp> 11‐vascular‐targeted photodynamic ( <scp>VTP</scp> ) therapy

Caroline M. Moore, A.R. Azzouzi, Éric Barret et al. · British Journal of Urology · 2014 · 89 citations

Medicine, Oncology, Surgery +17

Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials)

A. Noweski, Alexander Roosen, Souhil Lebdai et al. · European Urology Focus · 2018 · 67 citations · Full text

Medicine, Oncology, Biophotonics +15

Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results

V. Pierrard, Souhil Lebdai, F. Kleinclauss et al. · The Journal of Urology · 2018 · 26 citations · Full text

Medicine, Oncology, Surgery +17

Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: Results of prostate cancer Latin-American multicenter study

José Arturo Rodríguez-Rivera, R. Rodriguez-Lay, L. Zegarra-Montes et al. · Actas Urológicas Españolas (English Edition) · 2018 · 12 citations

Medicine, Oncology, Pharmacology +11